BR112020000209A8 - moléculas de ligação que modulam uma atividade biológica expressa por uma célula - Google Patents

moléculas de ligação que modulam uma atividade biológica expressa por uma célula

Info

Publication number
BR112020000209A8
BR112020000209A8 BR112020000209A BR112020000209A BR112020000209A8 BR 112020000209 A8 BR112020000209 A8 BR 112020000209A8 BR 112020000209 A BR112020000209 A BR 112020000209A BR 112020000209 A BR112020000209 A BR 112020000209A BR 112020000209 A8 BR112020000209 A8 BR 112020000209A8
Authority
BR
Brazil
Prior art keywords
biological activity
binding
cell
modulate
binding molecules
Prior art date
Application number
BR112020000209A
Other languages
English (en)
Other versions
BR112020000209A2 (pt
Inventor
Cornelis De Kruif Adriaan
Anna Wilhelmina Geuijen Cecilia
Throsby Mark
Johannes Tacken Paulus
Klooster Rinse
Logtenberg Ton
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of BR112020000209A2 publication Critical patent/BR112020000209A2/pt
Publication of BR112020000209A8 publication Critical patent/BR112020000209A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a invenção fornece meios e métodos para inibir uma atividade biológica das células. em uma concretização, a invenção se refere a um método de inibir uma atividade biológica em uma primeira ou segunda célula mediada pela ligação de duas proteínas de membrana que são parceiras de ligação entre si. a atividade biológica mencionada é inibida fornecendo às células um anticorpo ou molécula semelhante a anticorpo que pode se ligar a cada um dos parceiros de ligação mencionados e a ligação bloqueia a ligação dos dois parceiros de ligação, inibindo, assim, a atividade biológica mencionada.
BR112020000209A 2017-07-06 2018-07-06 moléculas de ligação que modulam uma atividade biológica expressa por uma célula BR112020000209A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17180064 2017-07-06
EP17180064.2 2017-07-06
PCT/NL2018/050449 WO2019009726A1 (en) 2017-07-06 2018-07-06 BINDING MOLECULES FOR MODULATING THE BIOLOGICAL ACTIVITY EXPRESSED BY A CELL

Publications (2)

Publication Number Publication Date
BR112020000209A2 BR112020000209A2 (pt) 2020-07-21
BR112020000209A8 true BR112020000209A8 (pt) 2020-08-11

Family

ID=59295094

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020000209A BR112020000209A8 (pt) 2017-07-06 2018-07-06 moléculas de ligação que modulam uma atividade biológica expressa por uma célula

Country Status (14)

Country Link
US (2) US11667714B2 (pt)
EP (1) EP3649154A1 (pt)
JP (2) JP7438098B2 (pt)
KR (1) KR20200037791A (pt)
CN (1) CN111094347A (pt)
AU (1) AU2018296067B2 (pt)
BR (1) BR112020000209A8 (pt)
CA (1) CA3068929A1 (pt)
EA (1) EA202090003A1 (pt)
IL (1) IL271817A (pt)
PH (1) PH12020550011A1 (pt)
SG (1) SG11202000014UA (pt)
TW (1) TW201920264A (pt)
WO (1) WO2019009726A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202090005A1 (ru) * 2017-07-06 2020-06-18 Мерус Н.В. Антитела, модулирующие биологическую активность, проявляемую клеткой
WO2019190327A2 (en) * 2018-03-30 2019-10-03 Merus N.V. Multivalent antibody
SG11202104864QA (en) * 2018-11-13 2021-06-29 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
TW202102544A (zh) * 2019-04-04 2021-01-16 日商小野藥品工業股份有限公司 雙特異性抗體
US11208486B2 (en) * 2019-04-26 2021-12-28 I-Mab Biopharma Us Limited Human PD-L1 antibodies
KR20220017909A (ko) 2019-05-09 2022-02-14 메뤼스 엔.페. 단백질 다량체화를 위한 변이체 도메인 및 그의 분리
AU2021329378A1 (en) 2020-08-19 2023-03-23 Xencor, Inc. Anti-CD28 compositions
CN113416249B (zh) * 2020-10-21 2023-04-07 北京智仁美博生物科技有限公司 针对破伤风毒素的组合物
KR20230135637A (ko) * 2021-01-28 2023-09-25 넥스트포인트 테라퓨틱스, 인코포레이티드 새로운 활성을 갖는 hhla2 결합제
EP4314061A1 (en) 2021-03-31 2024-02-07 Merus N.V. Novel multispecific antibodies
KR20230163503A (ko) * 2021-03-31 2023-11-30 메뤼스 엔.페. 신규한 pd-1 결합 도메인
CN114702569B (zh) * 2022-05-25 2023-01-10 深圳吉诺因生物科技有限公司 Pd-l1相关疫苗及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2288600C (en) 1997-05-02 2010-06-01 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
ES2368733T3 (es) 2002-07-18 2011-11-21 Merus B.V. Producción recombinante de mezclas de anticuerpos.
ES2427646T5 (es) * 2005-05-09 2017-08-22 Ono Pharmaceutical Co., Ltd. Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
RU2731084C2 (ru) 2008-06-27 2020-08-28 Мерюс Н.В. Продуцирующие антитела млекопитающие, не являющиеся человеком
HUE034832T2 (hu) 2008-12-09 2021-12-28 Hoffmann La Roche Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására
KR102382304B1 (ko) 2012-04-20 2022-04-04 메뤼스 엔.페. Ig-유사 분자의 제조방법 및 제조수단
CN105051066B (zh) 2012-09-27 2019-08-06 美勒斯公司 作为T细胞衔接器的双特异性IgG抗体
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها

Also Published As

Publication number Publication date
CN111094347A (zh) 2020-05-01
EA202090003A1 (ru) 2020-06-18
JP2020532280A (ja) 2020-11-12
IL271817A (en) 2020-02-27
BR112020000209A2 (pt) 2020-07-21
JP7438098B2 (ja) 2024-02-26
CA3068929A1 (en) 2019-01-10
SG11202000014UA (en) 2020-01-30
PH12020550011A1 (en) 2020-10-12
AU2018296067A1 (en) 2020-01-30
KR20200037791A (ko) 2020-04-09
US20200325227A1 (en) 2020-10-15
US20240034794A1 (en) 2024-02-01
JP2023171782A (ja) 2023-12-05
WO2019009726A1 (en) 2019-01-10
AU2018296067B2 (en) 2021-06-10
EP3649154A1 (en) 2020-05-13
US11667714B2 (en) 2023-06-06
TW201920264A (zh) 2019-06-01

Similar Documents

Publication Publication Date Title
BR112020000209A8 (pt) moléculas de ligação que modulam uma atividade biológica expressa por uma célula
BR112019005895A2 (pt) moléculas de ligação que modulam uma atividade biológica expressa por uma célula
BR112019000512A2 (pt) anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
WO2019060917A3 (en) METHODS AND COMPOSITIONS FOR SCREENING AND IDENTIFYING SPREADING MODULATORS
BR112018008068A2 (pt) moléculas de ligação que inibem o crescimento do câncer
BR112018070998A2 (pt) proteínas de ligação triespecíficas e/ou trivalentes
BR112020002012A8 (pt) Anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39
BR112018013883A2 (pt) membros de ligação com domínios de arcabouço de diversidade alterada
BR112017027582A2 (pt) método para inibição do crescimento de uma célula tumoral ou promoção da eliminação de uma célula tumoral, e, composição farmacêutica.
BR112017023829A2 (pt) agentes de ligação biespecíficos de antígeno de membrana específico da próstata (psma) e usos dos mesmos
BR112017017025A2 (pt) métodos e composições para analizar componentes celulares
BR112018010939A2 (pt) método utilizando anticorpos biespecíficos
BR112018006237A2 (pt) proteínas de ligação a pd-1 e métodos de uso das mesmas
BR112018072485A2 (pt) proteínas de ligação biespecíficas e usos das mesmas
BR112018000768A2 (pt) anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
BR112018006531A2 (pt) proteína isolada de ligação ao antígeno (abp), polinucleotídeo isolado, vetor, célula hospedeira, método para produzir uma proteína isolada de ligação ao antígeno (abp), composição farmacêutica, método para tratar ou prevenir uma doença ou condição num sujeito em necessidade deste, método para modular uma resposta imune num indivíduo em necessidade deste e kit
BR112018071686A2 (pt) exibição de proteínas integrais de membrana em vírions extracelulares envelopados de poxvírus
BR112016024515A2 (pt) proteínas do agonista do receptor trail de cadeia única
BR112017009006A2 (pt) molécula de ligação, polinucleotídeo isolado, vetor, célula hospedeira, método de produção da molécula de ligação, composição farmacêutica, uso da molécula de ligação e método de tratamento de uma doença em um indivíduo
BR112017026042A2 (pt) métodos e produtos para síntese de proteína de fusão
BR112017020054A2 (pt) anticorpos para icos
EA201492253A1 (ru) Конструкторы, связывающиеся с ron, и способы их использования
AR095596A1 (es) Moléculas de unión de cadena única comprendiendo n-terminal abp
BR112015019879A2 (pt) Composições de espécies de variantes moduladas de lisina e métodos para produção e uso das mesmas
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.